Notably, preclinical results have demonstrated robust anti-tumor efficacies of various FGFR-selective, small-molecule inhibitors such as AZD4547, BGJ398, and LY2874455 in FGFR2-amplified GC cell lines [7]. Here, FGFR2 is linked to neoplasm.